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ABSTRACT
Background: It is well known that anti-GAD (glutamic
acid decarboxylase) serves as a marker for
development of autoimmune diabetes in adults. On the
other hand, the clinical implications of anti-GAD
positivity in persistently non-diabetic (PND) adults
are poorly elucidated. Our aim was to establish
the frequency of anti-GAD in PNDs in an all-
population-based cohort from the Nord-Trøndelag
health study (HUNT) and to prospectively test for
associations with glucose tolerance and thyroid
autoimmunity.
Methods: We formed a primary study population
(4496 individuals), selected randomly from the age
group 20–90 years (50% men/women), who were
non-diabetic both at HUNT2 (1995–1997) and HUNT3
(2006–2008). Anti-GAD-positive individuals at HUNT2,
together with anti-GAD-negative individuals aged
20–29 years, were retested for anti-GAD positivity at
HUNT3. A secondary study population consisted of
individuals with type 2 diabetes (T2D, n=349) at
HUNT3 who developed diabetes between HUNT2
and HUNT3.
Results: The frequency of anti-GAD positivity in PND
was 1.7% (n=76) at HUNT2. Positivity did not
associate with gender, family history of diabetes, or
glucose levels, but was associated with thyroid-
associated autoimmunity (increased frequency of
positivity for anti-TPO (thyroid peroxidase), p<0.002).
HLA-DQA1/DQB1, a risk haplotype for autoimmunity,
was also associated with anti-GAD positivity in PND.
The incidence of anti-GAD positivity was low (0.4%) in
the subsample of individuals who were anti-GAD
negative in HUNT2. Anti-GAD positivity in PNDs was
frequently evanescent, with 54% losing, usually low-
grade, positivity between HUNT2 and HUNT3.
An evanescent state of autoimmunity as assessed by
anti-GAD positivity during “pre-diabetes” in individuals
later diagnosed with T2D could, however, not be
affirmed.
Conclusions: Anti-GAD positivity in PND is associated
with HLA risk haplotypes and thyroid autoimmunity but
not with clinical parameters of diabetes. Fleeting anti-
GAD positivity is common; however, results do not
support the notion of a history of autoimmunity in T2D
in the present cohort.
INTRODUCTION
Development of autoimmune diabetes is
strongly associated with the presence of auto-
antibody markers and the most commonly
used antibody for diagnostic purpose is
glutamic acid decarboxylase (anti-GAD).
This antibody is present in over 80% of
patients with type 1 diabetes who develop
disease during childhood or adolescence.1
Anti-GAD and other antibodies against
pancreatic antigens can often be detected
many years before the clinical onset of
autoimmune-mediated diabetes, indicating a
long “pre-diabetic” phase of autoimmune
activity.2 3 Studies which identify individuals
at risk of autoimmune diabetes by antibodies
have mainly investigated relatives of patients
with type 1 diabetes.4 5 There are limited
data available on antibody proﬁling in the
general population. Prospective epidemio-
logical data have shown that many indivi-
duals who develop autoimmune diabetes, in
particular latent autoimmune diabetes in the
adult (LADA),6 have antibodies before the
onset of diabetes and then usually in con-
junction with a family history of diabetes.
However, studies both in adults6–8 and in
children9 10 have shown that antibodies, in
particular anti-GAD, are also present in a pro-
portion of non-diabetic individuals who do
not develop diabetes over many years and
who do not have close relatives with auto-
immune diabetes. The frequency of anti-GAD
positivity in such non-diabetic individuals
varies between studies (0.7–4.8%) and the
clinical importance of positivity is debated. It
has been argued that positivity under these
conditions has no bearing on autoimmune
diabetes,11 12 that it is unspeciﬁc (particularly
if it is weak), or that it should be regarded as
falsely positive.13 There is a scarcity of large
and prospective epidemiological studies
which are population-based and which
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speciﬁcally address the issue of persistently antibody-
positive non-diabetic individuals.
The primary aim of the present study was to investi-
gate the presence, persistence, and potential clinical
implications of anti-GAD positivity in persistently non-
diabetic adults. For this purpose, we prospectively ana-
lyzed relevant data in a large non-diabetic adult
population-based cohort collected from the Norwegian
Health Study in Nord-Trøndelag (HUNT). On ﬁnding
positivity disappearing with time in many individuals, we
also tested whether some antibody-negative individuals
who were classiﬁed as having type 2 diabetes in the third
HUNT survey could have displayed signs of autoimmun-
ity (ie, anti-GAD positivity) prior to diabetes.
MATERIAL AND METHODS
Study population
The study is based on the second and third health
surveys (HUNT2 and HUNT3) in Nord-Trøndelag
county in Norway. HUNT2 was performed in 1995–1997
and HUNT3 in 2006–2008. Details about the HUNT
study have been published previously.14 Brieﬂy, the
surveys represent 69% (HUNT2) and 54% (HUNT3) of
the entire adult population of Nord-Trøndelag county.
For our analysis, we collected a random sample from
37 059 adults ≥20 years of age who took part in the
HUNT2 and HUNT3 surveys, comprising about 40% of
all adults in the county.
Equal numbers of men and women without diabetes,
identiﬁed by self-reported answers of ‘No’ to the question
“Do you have or have had diabetes?” at both surveys (in
the following termed persistently non-diabetic indivi-
duals), were randomly selected from different age
groups: 500 individuals aged 20–29, 500 aged 30–34, 500
aged 35–39, etc, up to the last age group with 500
individuals aged from 65 years and above. Altogether,
we sampled a total of 4500 persistently non-diabetic
individuals to represent the general adult population
(ﬁgure 1). These individuals constituted our primary
study population. Serum specimens from HUNT2 to be
used for anti-GAD measurements were available for 4496
of the 4500 selected individuals. All individuals who were
found to be anti-GAD positive in HUNT2 were analyzed
for positivity in HUNT3. Additionally, we also tested for
anti-GAD in HUNT3 in a subset of the anti-GAD-negative
individuals. The subset comprised all randomly
selected anti-GAD-negative individuals at HUNT2 who
were 20–29 years of age at HUNT2. This age group was
selected since age in HUNT3 corresponded with the 30–
39 year age group in HUNT2 which displayed the highest
frequency of anti-GAD positivity.
We also included 53 adults with incident autoimmune
diabetes from HUNT3 (reported not having diabetes in
HUNT2 but reported having diabetes in HUNT3, ie
individuals who developed diabetes between HUNT2
and HUNT3, ﬁgure 1) for comparison with our primary
study population. Some results on these individuals have
been published previously.2 Individuals were classiﬁed as
having type 1 diabetes if they started insulin treatment
within 12 months of diagnosis and were antibody posi-
tive or antibody negative, but in addition had fasting C
peptide levels <150 pmol/L. Individuals were classiﬁed
as having LADA if they were antibody positive at diagno-
sis and had not been treated with insulin within
12 months of diagnosis. No age limit was set for LADA.
A subset of 32 of these 53 individuals was anti-GAD
Figure 1 Flow sheet over the
primary study population as well
as comparative individuals of
“pre-diabetic” individuals followed
from HUNT2 to HUNT3 (GAD,
glutamic acid decarboxylase; neg,
negative; pos, positive).
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positive already at HUNT2 without a diagnosis of dia-
betes. Data from these 32 individuals who with time
developed autoimmune diabetes and were anti-GAD
positive prior to diabetes diagnosis, hereafter called
autoimmune “pre-diabetic” individuals (“pre-diabetic”
since we know that these individuals developed diabetes
later), were compared with those from our primary
study population who were anti-GAD positive and persist-
ently non-diabetic.
To further study the time dynamics of anti-GAD in the
HUNT cohort, we also investigated 349 individuals with
incident type 2 diabetes in HUNT3, in whom anti-GAD
could be analyzed in serum samples collected at
HUNT2 (ie, years before diagnosis of diabetes).
Classiﬁcation of type 2 diabetes at HUNT3 was based on
individuals being anti-GAD negative and not treated
with insulin within 12 months of diagnosis.
Antibody assays
The serum samples used to analyze anti-GAD were
stored at the HUNT Biobank, Levanger, Norway, at
minus 80°C until analyzed. The samples were assayed
for anti-GAD at the Hormone Laboratory, Department
of Medical Biochemistry, Oslo University Hospital, Oslo,
Norway. Anti-GAD was measured by immune precipita-
tion using 3H leucine translation-labeled GAD65 as
the reagent (Novo Nordisk, Bagsværd, Denmark).
Separation of bound anti-GAD and free labeled GAD65
was performed by protein A+C coupled to Sepharose.
Antibody levels were expressed as an antibody index (ai,
method range ≥0.01ai) relative to a standard serum
given by the formula ((counts per minute (CPM) in the
patient’s sample—cpm from the negative reference
sample)/(cpm of a positive reference sample—cpm
from the negative reference sample)). We have used two
different cut-offs for positivity, namely ≥0.06ai and
≥0.08ai. On the basis of the Hormone Laboratory’s par-
ticipation in the Diabetes Autoantibody Standardization
Program (DASP), the cut-off of 0.06ai gave a 82% DASP
sensitivity and a 99% DASP speciﬁcity (from the 2010
DASP), and the cut-off of 0.08 gave a 64% DASP sensitiv-
ity and a 100% DASP speciﬁcity (from 2003 DASP). The
intra-assay coefﬁcient of variation (CV) was 14% in the
lowest range (0.11ai), 8% in the middle range (0.22ai)
and 17% in the highest range of measurements (2.0ai).
The total CV was 19% in the lowest range (0.21ai) and
23% in the highest range of measurements (0.66ai).
Analysis of thyroid peroxidase antibody (anti-TPO)
was implemented as a baseline measurement in HUNT2
and HUNT3. In HUNT2, anti-TPO was measured in all
participants with measurements of thyroxin-stimulating
hormone (TSH) >4.0 mU/L and additionally in a 3%
randomly selected group of participants of HUNT2.
Measurements of anti-TPO were performed in non-
fasting serum samples at the Hormone Laboratory, and
were analyzed by luminous immunoassay technology.
The instrument range was 201–9999 kIE/L and
intra-assay CV was 11% in the low range (214 kIE/L),
9% in the middle range (412 kIE/L), and 5% in the
high range (2300 kIE/L). In HUNT3, anti-TPO was
measured in all participants with measurements of
TSH<0.10 mU/L or TSH>3.00 mU/L. The measure-
ments were performed in non-fasting serum at Levanger
Hospital, Levanger, Norway, and were analyzed by
chemiluminescent microparticle immunoassay technol-
ogy. The instrument range was 0.01–1000 IU/mL and
intra-assay CV was 18.5% in the low range (0.7 IU/mL)
and 3.3% in the high range (72.8 IU/mL).
By combining results on anti-TPO from HUNT2 (posi-
tivity ≥200 kIE/L) and HUNT3 (positivity >5.1 IU/mL),
we obtained data on anti-TPO from 502 (mean age 60.6
±13.2 and 42% men) of 4496 individuals.
HLA typing
Persistently non-diabetic individuals who were anti-GAD
positive at HUNT2 as well as a control group of
anti-GAD-negative non-diabetic individuals were typed
for HLA-DQA1 and HLA-DQB1. The control group was
age-matched and gender-matched to the anti-GAD-
positive, non-diabetic group. Two controls were selected
per anti-GAD-positive individual.
HLA-DQA1 and HLA-DQB1 genotypes were analyzed
at the Unit for Immunology, St. Olavs Hospital,
Trondheim, Norway, by sequence-speciﬁc oligonucleotide
probes using LABTypeR SSO DQA1/DQB1 Typing Tests
(One Lambda Inc, California, USA), as described by the
manufacturer. In brief, the target DNA was ampliﬁed by
PCR using HLA-locus speciﬁc target primers. The ampli-
ﬁed target DNA was denatured and rehybridized with
complementary DNA probes bound to ﬂuorescently
coded microspheres, which allowed detection using
R-Phycoerythrin-bound Streptavidin. The ﬂow analyzer
Luminex 100 (Luminex Corporation, Texas, USA) was
used to measure the ﬂuorescent signal of Phycoerythrin
and the HLA fusion 2.0 (One Lambda Inc, California,
USA) software was used to process the results.
The HLA DQA1-DQB1 haplotypes were divided into
the following four groups based on known type 1 dia-
betes risk: (1) very high risk, having the genotype
DQA1*0301-DQB1*0302/DQA1*0501-DQB1*0201; (2)
high risk, having the genotypes DQA1*0301-DQB1*0302/
Z, DQA1*0501-DQB1*0201/Z or DQA1*X-DQB1*0302/
DQA1*X-DQB1*X; (3) neutral, having DQA1*X-DQB1*X/
DQA1*X-DQB1*X; (4) strongly protective, having either
the genotype DQA1*X-DQB1*0602/DQA1*X-DQB1*0603
or one of these haplotypes in combination with one of
the haplotypes DQA1*X-DQB1*0302 or DQA1*X-DQB1*X
(see table 3 for more details). For groups 2–4, X indi-
cates a non-deﬁned allele and Z indicates any haplotype
deﬁned and non-deﬁned except DQA1*0301-DQB1*0302
and DQA1*0501-DQB1*0201 (potential homozygosity
was not excluded).
Statistical analysis
Data are given as numbers and percentage for categorical
data and as median (minimum–maximum value) for
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continuous data. All statistical analyses were performed
by the PASW Statistics (V.20, SPSS, Inc, Chicago, Illinois,
USA). χ2 Test or Fisher’s exact test (when appropriate)
was used to compare differences in categorical data. The
Mann-Whitney U test was used to test differences in con-
tinuous data between two groups. The Kruskal-Wallis test
was used to test differences in continuous data between
more than two groups. Logistic regression models were
used to examine whether HLA haplotypes were asso-
ciated with anti-GAD after adjusting for other confound-
ing factors such as age, gender, body mass index (BMI),
and ﬁrst-degree family history of diabetes. A two-tailed
p value of 0.05 was considered to be signiﬁcant.
Ethics
All participants gave their written consent. The study
was approved by the Regional Committee for Ethics in
Medical Research.
RESULTS
Frequency of anti-GAD in persistently non-diabetic
individuals
Seventy-six of 4496 persistently non-diabetic individuals
in HUNT3 (1.7%) tested positive for anti-GAD in
HUNT2 when using a cut-off of 0.06ai (median level
0.08ai with minimum–maximum values of 0.06–3.58ai).
The age group with the highest frequency was 30–34
years (16 of 499, 3.2%). The age group with the lowest
frequency was 45–49 years (2 of 499 individuals, 0.4%,
ﬁgure 2). There were no signiﬁcant differences in fre-
quency between sexes. When using 0.08ai as a cut-off for
anti-GAD positivity, 41 (0.9%) persistently non-diabetic
individuals tested positive in HUNT2 (median level
0.23ai with minimum–maximum values of 0.08–3.58ai).
In the following, the results are presented using the
cut-off of 0.06ai as anti-GAD positivity if not otherwise
stated.
Anti-GAD positivity in relation to clinical data
Positivity for anti-GAD was not associated with smoking,
non-fasting glucose, or BMI (table 1).
Nor was there an association with ﬁrst-degree family
history of diabetes (overall). When splitting ﬁrst-degree
family history of diabetes into parents, siblings, and chil-
dren, there tended to be a higher risk of being
anti-GAD positive in those who had siblings with
diabetes (OR (95% CI) 1.96 (0.83 to 4.51), p=0.14, 8.2%
(6 of 73 individuals) vs 4.4% (190 of 4292 individuals)).
Anti-GAD disappearance with time
Of the 76 initially anti-GAD-positive adults in HUNT2, a
majority, that is, 41 (53.9%), converted to negative in the
follow-up sample in HUNT3. There were no phenotypic
differences between persistently anti-GAD-positive indivi-
duals compared with transiently anti-GAD-positive indivi-
duals (table 2). However, the initial anti-GAD levels in
HUNT2 was higher in persisters compared with conver-
ters, with a median level (minimum–maximum value) of
0.27ai (0.06–3.58 ai) versus 0.06ai (0.06–1.34 ai) (p<0.01
for difference).
Cumulative incidence of anti-GAD in an initially
anti-GAD-negative population subset
Of the initially 495 anti-GAD-negative adults in the age
group 20–29 years at HUNT2, we could sample 485
Figure 2 Frequency of anti-GAD (glutamic acid decarboxylase) positivity in the adult population of the HUNT2 survey
distributed across different age categories.
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serum samples from HUNT3. These samples were then
analyzed for anti-GAD positivity. Only two individuals
were found to be positive (0.06ai and 0.42ai), giving an
11-year cumulative incidence of 0.4%.
Anti-GAD-positive non-diabetic persisters display less
diabetogenic traits than anti-GAD-positive autoimmune
“pre-diabetic” individuals
We compared (table 2) persistently non-diabetic indivi-
duals who were anti-GAD positive at HUNT2 (n=76) with
autoimmune “pre-diabetic” individuals who were
anti-GAD positive and non-diabetic at HUNT2 but had
developed diabetes prior to or at HUNT3 (n=32). Actual
values of anti-GAD in HUNT2 and HUNT3 of persistent
non-diabetic (divided into persistently and transiently
anti-GAD positive) versus autoimmune ‘pre-diabetic’
individuals are shown in online supplementary ﬁgure S1.
Autoimmune “pre-diabetic” individuals displayed a
higher frequency of ﬁrst-degree family history of dia-
betes compared with those who remained non-diabetic
(p<0.01). This difference was also signiﬁcant after
adjusting (by logistic regression) for HLA genotypes,
sex, age, and BMI (OR 3.24 (1.22 to 8.62), p=0.02).
Autoimmune “pre-diabetic” individuals at HUNT2 also
displayed signiﬁcantly higher anti-GAD levels (p<0.01)
and non-fasting glucose levels (p<0.01). In addition,
they were more obese (higher waist circumference and
BMI, p=0.01 and p=0.02, respectively) compared with
the persistently non-diabetic individuals. Removing
those of the latter who became anti-GAD negative in
HUNT3 (n=41) from the analysis did not alter the differ-
ences between the persistently non-diabetic and auto-
immune “pre-diabetic” individuals (data not shown).
No evidence for fleeting autoimmunity during
“pre-diabetes” in type 2 diabetic individuals
On ﬁnding a major and unexpected rate of disappear-
ance of anti-GAD positivity from HUNT2 to HUNT3, we
reasoned that a similar process could possibly include a
“pre-diabetic” period of ﬂeeting autoimmune activity in
individuals who are later diagnosed with type 2 diabetes
on the basis of negative testing for autoimmune anti-
bodies. To exclude such a clinically important possibility,
we sampled 349 serum samples from HUNT2 adults
who reported not having diabetes in HUNT2 but who
were classiﬁed as having type 2 diabetes in HUNT3.
None of these individuals were found to be anti-GAD
positive in the “pre-diabetic” state (HUNT2).
Anti-GAD positivity in persistently non-diabetic individuals
associates with HLA risk haplotypes
Seventy-ﬁve anti-GAD-positive and 151 anti-GAD-negative
persistently non-diabetic individuals were successfully
genotyped for HLA DQA1-DQB1. We found no differ-
ences regarding the clinical characteristics when com-
paring the anti-GAD-positive and anti-GAD-negative
groups (data not shown). However, having very high-risk
or high-risk HLA genotypes was associated with being
anti-GAD positive (table 3) after adjusting for age, sex,
BMI, and ﬁrst-degree family history of diabetes (OR
(95% CI) 9.57 (2.16 to 42.16), p<0.01 and OR 2.21
(1.02 to 4.77), p=0.04, respectively).
Removing the converters (ie, those who became
anti-GAD negative in HUNT3, n=41) from the analysis
did not materially affect the results (data not shown).
Comparing only the converters with the anti-GAD-
negative ones showed a trend for associations between
Table 1 Clinical characteristics of persistently non-diabetic individuals stratified by being anti-GAD negative and anti-GAD
positive in HUNT2
Anti-GAD negative Anti-GAD positive p Value
N 4420 76 (1.7%)
Sex (male) 2208 (50.0%) 40 (52.6%) 0.64
Age at attendance 48 (19–85) 42 (21–77) 0.22
Waist circumference (cm) 86 (55–131) 84 (64–109) 0.69
BMI (kg/m2) 25.6 (16.2–52.8) 26.0 (19.4–34.8) 0.70
Systolic blood pressure (mm Hg) 133 (82–225) 132 (102–189) 0.82
Diastolic blood pressure (mm Hg) 79 (44–136) 78 (52–120) 0.85
Glucose, non-fasting (mmol/L) 5.1 (2.6–14.4) 5.1 (3.5–7.5) 0.89
Cholesterol (mmol/L) 5.8 (1.9–13.2) 5.7 (3.4–8.2) 0.35
HDL cholesterol (mmol/L) 1.4 (0.5–3.8) 1.3 (0.6–2.4) 0.62
Triacylglycerol (mmol/L) 1.4 (0.3–18.6) 1.3 (0.2–4.7) 0.30
Family history of diabetes
No 3229 55
Yes 1181 (26.8%) 21 (27.6%) 0.86
Smoking
No 3224 59
Yes 1052 (24.9%) 17 (22.4%) 0.65
Data are given as numbers (%) and median (minimum–maximum value).
Unadjusted p value calculated by the Mann-Whitney U test for continuous data and by the χ2 test for categorical data.
BMI, body mass index; GAD, glutamic acid decarboxylase; HDL, high-density lipoprotein.
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Table 2 Clinical characteristics from HUNT2 of (1) anti-GAD-positive and initially non-diabetic individuals at HUNT2 (stated to be not having diabetes), divided into
autoimmune “pre-diabetic” (stated to be having diabetes in HUNT3) and persistently non-diabetic individuals (still non-diabetic in HUNT3), (2) anti-GAD-positive converters
and persisters measured in HUNT3 in persistently non-diabetic participants
(1) Autoimmune
“pre-diabetic”*
Anti-GAD positive
HUNT2
(1) Persistently
non-diabetic†
Anti-GAD positive
HUNT2
p
Value‡
(2) Persistently non-diabetic
converters§
Anti-GAD negative HUNT3
(2) Persistently non-diabetic
persisters¶
Anti-GAD positive
HUNT3
p
Value**
N 32 76 41 35
Sex (male) 17 (53.1%) 40 (52.6%) 1.00 19 (46.3%) 21 (60.0%) 0.24
Age at attendance 50 (26–76) 42 (21–77) 0.19 44 (22–77) 40 (21–66) 0.24
Waist circumference (cm) 92 (65–109) 84 (64–109) 0.01 82 (64–120) 85 (64–106) 0.24
BMI (kg/m2) 27.8 (20.9–39.6) 26.0 (19.4–34.8) 0.02 25.6 (19.4–34.2) 26.3 (19.4–34.8) 0.32
Systolic blood pressure (mm Hg) 137 (107–190) 131 (102–189) 0.05 131 (102–188) 132 (104–189) 0.89
Diastolic blood pressure (mm Hg) 85 (58–122) 78 (53–120) 0.05 78 (60–120) 79 (53–105) 0.81
Glucose, non-fasting (mmol/L) 5.5 (4.1–10.0) 5.1 (3.5–7.1) <0.01 5.2 (3.5–7.5) 5.0 (3.7–7.1) 0.90
Cholesterol (mmol/L) 6.0 (3.4–7.6) 5.7 (3.4–8.2) 0.22 5.5 (3.4–8.2) 5.8 (4.1–7.8) 0.74
HDL cholesterol (mmol/L) 1.3 (0.7–2.4) 1.3 (0.6–2.4) 0.24 1.3 (0.7–2.4) 1.4 (0.6–2.2) 0.84
Triacylglycerol (mmol/L) 1.6 (0.6–7.8) 1.3 (0.2–4.7) 0.13 1.3 (0.2–4.0) 1.3 (0.6–4.7) 0.73
Anti-GAD level (ai) 1.44 (0.07–1.98) 0.08 (0.06–3.58) <0.01 0.06 (0.06–1.34) 0.27 (0.06–3.58) <0.01
Family history of diabetes 18 (56.3%) 21 (27.6%) <0.01 12 (29.3%) 9 (25.7%) 0.80
Smoking (currently) 12 (37.5%) 17 (22.4%) 0.15 11 (26.8%) 6 (17.1%) 0.41
Data are presented as n (%) or median (minimum–maximum values).
*Autoimmune “pre-diabetic”; individuals having autoimmune diabetes in HUNT3 (type 1 diabetes (n=13) and LADA (n=21)), but reported not having diabetes and did not have non-fasting
glucose <11 mmol/l in HUNT2.
†Persistently non-diabetic; individuals who were non-diabetic both at HUNT2 and HUNT3.
‡Unadjusted p value calculated by the Mann-Whitney U test for continuous data and by Fisher’s exact test for categorical data. Comparison between anti-GAD-positive autoimmune
“pre-diabetic” and persistently non-diabetic individuals.
§Persistently non-diabetic converters; anti-GAD positive in HUNT2 and converted to being negative in HUNT3.
¶Persistently non-diabetic persisters; anti-GAD positive in HUNT2 and HUNT3.
**Unadjusted p value calculated by the Mann-Whitney U test for continuous data and by Fisher’s exact test for categorical data. Comparison between anti-GAD-positive converters and
persisters among the persistently non-diabetic individuals.
ai, Antibody index; BMI, body mass index; GAD, glutamic acid decarboxylase; HDL, high-density lipoprotein; LADA, latent autoimmune diabetes in adult.
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anti-GAD positivity and HLA risk haplotypes (very high-
risk OR 5.51 (0.72 to 42.26), p=0.10, high-risk OR 2.14
(0.77 to 5.93), p=0.14 and neutral OR 2.27 (0.79 to
6.54), p=0.13) after adjusting for age, sex, BMI, and ﬁrst-
degree family history of diabetes.
Anti-GAD positivity in persistently non-diabetic individuals
associates with thyroid autoimmunity
We tested if anti-GAD positivity was associated with anti-
TPO positivity using data from 502 individuals with mea-
sures on both. Within the anti-GAD positive individuals
(n=14), 78.6% were also anti-TPO positive (n=11). In
contrast, of the anti-GAD negative individuals (n=488),
only 36.7% were anti-TPO positive (n=179) (p<0.01 for
difference). There were no other clinical differences (as
listed in table 1) between the anti-GAD positive and
anti-GAD negative individuals within this subgroup (data
for subgroup not shown).
Results analyzed by a higher cut-off (0.08ai)
Anti-GAD positivity was still not associated with clinical
parameters of diabetes when using 0.08ai as a cut-off.
Seroconversion from HUNT2 to HUNT3 decreased to
about one-third (29.3%). There were still no phenotypic
differences between persisters compared with conver-
ters, and converters had lower anti-GAD levels.
Signiﬁcant differences between persistently non-diabetic
individuals compared with autoimmune “pre-diabetic”
individuals regarding parameters such as ﬁrst-degree
family history, anti-GAD, and non-fasting glucose levels
were upheld (data not shown). Association between
anti-GAD positivity and HLA risk haplotypes tended to
be stronger when using 0.08ai as a cut-off for positivity
(data not shown). Five of 7 (71.4%) anti-GAD-positive
individuals were also anti-TPO positive compared with
181 of 495 (36.6%) anti-GAD-negative ones (p=0.11).
DISCUSSION
In persistently non-diabetic individuals from a
population-based cohort from Norway with 11 years of
follow-up, we found a frequency of anti-GAD positivity of
1.7%. We found no signs of reduced glucose tolerance
in these anti-GAD-positive individuals, but there were
still associations with high-risk type 1 diabetes HLA gen-
otypes as well as with thyroid autoimmunity. Another
observation was the appreciable loss of positivity with
time. This ﬁnding opened the possibility of ﬂeeting posi-
tivity during the “pre-diabetes” state in patients classiﬁed
as type 2 diabetes. This possibility, based on measure-
ments of anti-GAD in such patients, could, however, not
be afﬁrmed.
Including autoimmune “pre-diabetic” individuals
together with the persistently non-diabetic individuals
the frequency of anti-GAD positivity increases from 1.7%
to 2.0%. This frequency is in fair agreement with most
previous reports in which frequencies range from 1% to
4% in children and adults from the general popula-
tion.5 6 8 15 In previous reports, a distinction was usually
not made as to whether diabetes developed over time or
not, nor to phenotypic characteristics and age as
described here. Here, the individuals studied were
sampled in a randomized and representative fashion to
encompass different ages and both sexes. From these
data, it seems clear that prevalent positivity was not over-
represented to a major extent by one sex, nor com-
pletely conﬁned to certain ages.
The incidence of anti-GAD in our population was
tested in a subset of our population, that is, those being
Table 3 Association of the HLA DQA1-DQB1 haplotypes compared between anti-GAD-negative and anti-GAD-positive
persistently non-diabetic individuals in HUNT2
Haplotype 1 Haplotype 2 Anti-GAD
OR (95% CI) p Value‡
HLA
DQA1-DQB1
HLA
DQA1-DQB1 Negative N=151 Positive N=75
Very high risk 0301–0302 0501–0201 3 (2.0) 8 (10.7) 9.57 (2.16 to 42.16) <0.01
High risk 0301–0302
0501–0201
X*-0302
Z†
Z
X-X
61 (40.4) 37 (49.3) 2.21 (1.02 to 4.77) 0.04
Neutral X-X X-X 45 (29.8) 18 (24.0) 1.46 (0.62 to 3.40) 0.39
Strong protective X-0602
X-0602
X-0602
X-0603
X-0603
X-0603
X-0603
X-0302
X-X
X-0602
X-0302
X-X
42 (27.8) 12 (16.0) 1.00
Data are given as numbers (%).
*X means a non-defined allele, but does not exclude potential homozygosity.
†Z means any haplotype, defined and non-defined, except DQA1*0301-DQB1*0302 and DQA1*0501-DQB1*0201; however, it does not
exclude potential homozygosity.
‡p Value calculated from logistic regression, corrected for age and BMI at HUNT2, sex, and first-degree family history of diabetes.
BMI, body mass index; GAD, glutamic acid decarboxylase.
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20–29 years old and anti-GAD negative in HUNT2. Only
two of these individuals developed positivity when
retested at HUNT3, that is, 11 years later, whereas there
was a much higher (2–3%) positivity among HUNT2
prevalent individuals in the corresponding age groups.
Perhaps then, the frequency data reﬂect to a large
extent positivity that developed before the age of
20 years and then persisted. Such a notion must,
however, be conﬁrmed by other studies.
In the persistently non-diabetic individuals, we could
not detect any clinical parameters conferring risk of dia-
betes (listed in table 1) that were associated with
anti-GAD positivity. Neither did the presence or absence
of stability of anti-GAD positivity (positivity or not both
in HUNT2 and HUNT3) affect the clinical parameters.
However, having high-risk HLA DQA1-DQB1 haplotypes
were associated with the presence of anti-GAD. This is in
line with a recent study mainly based on adult relatives
of individuals with type 2 diabetes reporting that
anti-GAD was also associated with HLA high-risk haplo-
types in the absence of a family history of type 1 diabetes
and evolution of diabetes.16
The notion that even a minor and ﬂeeting anti-GAD
positivity is coupled to autoimmunity is reinforced by
ﬁnding associations between anti-GAD positivity and
thyroid-associated autoimmunity. Hence, we found a clear
association of the presence of antibodies with TPO.
Whereas an association between type 1 diabetes as well as
LADA and thyroid autoimmune disease is well documen-
ted,17–19 an association with the presence of anti-GAD in
persistently non-diabetic individuals has, to the best of
our knowledge, not been previously reported.
Fleeting anti-GAD positivity raises the possibility that
individuals who had developed diabetes between
HUNT2 and HUNT3 and were classiﬁed as type 2 could
have been anti-GAD positive before diabetes diagnosis.
If so, they would belong to the category of LADA rather
than type 2 diabetes. This clinically important possibility
was contradicted by the lack of anti-GAD positivity in
this group. However, we cannot exclude the possibility of
ﬂeeting positivity for other antibodies in a subset of
patients classiﬁed as type 2 diabetes.
We compared two different cut-offs for anti-GAD
positivity and found that they gave essentially the
same results. This ﬁnding is a further indication that the
positivity for anti-GAD that we ﬁnd in persistently non-
diabetic individuals is not a statistical artifact.
A comparison of anti-GAD-positive persistently non-
diabetic individuals with autoimmune “pre-diabetic”
individuals (ie, anti-GAD positive, but non-diabetes at
HUNT2, diabetes diagnosis at HUNT3) revealed higher
titers of anti-GAD in HUNT2 in the latter. This could
signify higher autoimmune activity, which in turn could
precipitate overt diabetes in these individuals. However,
we note that risk factors for type 2 diabetes such as BMI
and age were also higher in the autoimmune “pre-
diabetic” individuals and could participate in the devel-
opment of diabetes.
In contrast to the Botnia study,16 we did not ﬁnd an
association between anti-GAD positivity and ﬁrst-degree
family history of diabetes in the non-diabetic individuals.
This difference between studies may be explained by
our questionnaire data which did not distinguish
between type 1 and type 2 family histories of diabetes.
The risk of developing type 1 diabetes and LADA is
reportedly highest in siblings of patients with dia-
betes.20 21 We did see a tendency for higher risk of
being anti-GAD positive in those individuals who had
siblings with diabetes.
There are limitations to be considered when interpret-
ing the results of this study. The number of
anti-GAD-positive individuals that we detected and ana-
lyzed was moderate (although large compared with pre-
vious studies), something which precluded a detailed
analysis of the inﬂuence of age and sex. Comparing
anti-GAD positivity with C peptide levels would have
added valuable data; however, the lack of fasting blood
samples made such comparisons impossible. That data
on thyroid autoimmunity are based on a subset of our
primary population is another limitation. Conﬁrming
results from other populations would be desirable.
A limitation by number also pertains to our incidence
data (only subset analysis was possible). As to method-
ology, one may argue that anti-GAD positivity should be
conﬁrmed by competition assays. However, the latter
type of analysis in a previous study did not detect any
unspeciﬁc inﬂuence between three different anti-GAD
assays.22 Stability of the anti-GAD assay is supported by
validation against DASP. However, ideally, the intraindivi-
dual variation of levels of anti-GAD should have been
ascertained by repeat measurements in a time perspec-
tive of weeks or months. Such repeated measurements
would have added conﬁrmation of the correctness of
the classiﬁcation into positivity or non-positivity for
anti-GAD.
We conclude that anti-GAD positivity in adult non-
diabetic individuals from the general population is not
restricted in terms of age and sex, is only partly
Key messages
▸ Anti-GAD can be detected many years before the clinical onset
of autoimmune diabetes, which indicate a long pre-diabetic
phase of autoimmune activity. The presence and clinical impli-
cations of anti-GAD positivity in persistently non-diabetic adults
are, however, poorly elucidated.
▸ Using the population from the second and third Nord-
Trøndelag Health Study, Norway, we found a frequency of
anti-GAD positivity of 1.7% in a sub-group of persistently
non-diabetic individuals.
▸ Our results show that there are no associations between anti-
GAD positivity and clinical parameters related to diabetes in
non-diabetic adults. However, anti-GAD positivity is associated
with high-risk HLA haplotypes linked to type 1 diabetes and
also thyroid autoimmunity.
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persistent over a long time period, and is not associated
with clinical parameters related to diabetes. However,
such positivity is associated with increased frequency of
high-risk HLA haplotypes linked to type 1 diabetes and
also with thyroid autoimmunity. Further, ﬂeeting
anti-GAD positivity during “pre-diabetes” does not seem
to be a factor behind the later development of diabetes
which is diagnosed as type 2 diabetes.
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